Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Cancer Genetics, Inc Awarded 3 Qualifying Therapeutic Discovery Project Grants | Cancer Genetics Incorporated

Abstract:
Cancer Genetics, Inc (CGI) granted over $735 thousand for research and development of unique diagnostic research for cancer

Cancer Genetics, Inc Awarded 3 Qualifying Therapeutic Discovery Project Grants | Cancer Genetics Incorporated

Rutherford, NJ | Posted on November 13th, 2010

Cancer Genetics, Inc (CGI), an emerging leader in personalized treatment for cancer, has been awarded 3 grants to further commercialize molecular diagnostics for oncology. CGI has announced that these grants were issued from the Qualifying Therapeutic Discovery Project program under section 48D of the Internal Revenue Code. This program was created under the Affordable Care Act and is aimed to fund projects and initiatives that demonstrate the ability to advance new therapies, reduce long-term healthcare costs, or take steps to curing cancer within the next 30 years. CGI's founder, Dr. R.S.K. Chaganti says, "The success with this award is a clear validation of CGI's novel approaches and innovative technologies towards taking molecular diagnostics of cancer to the next level." The three funded projects cover personalized treatment and diagnosis in the areas of: mature b-cell neoplasms, HPV-associated cancers, and renal cancer. CGI is expected to commercialize these products over the next year, with an initial launch in late November of 2010 of the lymphoma microarray, MatBA™.

The Qualifying Therapeutic Discovery Project program was allotted $1 billion for credits and grants to fund projects designed to improve health and save lives. The IRS, in conjunction with the Department of Health and Human Services, reviewed applications for projects that showed significant potential to produce new and cost-saving therapies, support jobs and increase U.S. competitiveness. Projects aimed in the determination of molecular factors through the use of molecular diagnostics to guide therapeutic decisions were highly regarded in the selection process. CGI aims to develop diagnostic assays for prognosis of cancer that help to guide effective treatments and reduce healthcare costs. The funding is geared towards making testing and diagnostic services more affordable, allow for further clinical trials, and educate medical personnel on the information and usage of CGI products.

Qualified Therapeutic Discovery Projects at CGI:

MatBA™

A microarray-based comparative genomic hybridization (CGH) assay developed to detect chromosomal gains and losses frequently observed in mature B-cell neoplasm. In MatBA™-CLL application, DNA gains and losses in chronic lymphocytic leukemia (CLL) are detected and physicians can utilize the results to assist in the diagnosis and prognosis of CLL.

FHACT™

Used as a patented-pending diagnostic tool, FHACT™ is a DNA-FISH based assay that can identify chromosomal changes in HPV-associated cancers. FHACT™, when used as a reflex test for abnormal cytology specimens, will provide a new level of triage to patients with an HPV-positive status. By identifying the type of abnormalities and the stage of cervical cancer progression, FHACT™ can be used to determine the most suitable treatment for the patient that is the least invasive and most cost-effective

FReCaD™

This FISH-based renal cancer detection (FReCaD) assay is designed to differentially diagnose the four main subtypes of renal cortical neoplasm. By detecting inherent genomic rearrangement to renal cancer subtypes, FReCaD assay allows a more accurate diagnosis and subsequently the determination of personalized clinical management leading to a higher remission rate and the prevention of disease progression.

####

About Cancer Genetics
Based in of Rutherford, NJ, CGI was founded by Dr. R.S.K. Chaganti in 1999 and has become an emerging leader in personalized cancer treatment. CGI’s synergistic business model provides cancer-focused diagnostic testing services to leading oncologists, pathologists, hospitals, and academics centers as well as the development of next-generation diagnostic products that leverage CGI’s unique IP in molecular genetics and oncology. Products developed by CGI are revolutionizing the management and treatment of certain cancers as well as reducing healthcare costs.

The company can be found on the Internet at www.cancergenetics.com or reached at (201) 528-9200.

For more information, please click here

Contacts:
Jessica Kissen

(201) 528-9196

Copyright © Cancer Genetics

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Advantest to Exhibit at SEMICON Korea in Seoul, South Korea February 4-6 Showcasing Broad Portfolio of Semiconductor Products, Technologies and Solutions January 29th, 2015

Park Systems Announces Innovations in Bio Cell Analysis with the Launch of Park NX-Bio, the only 3-in-1 Imaging Nanoscale Tool Available for Life Science Researchers January 29th, 2015

2015 Nanonics Image Contest January 29th, 2015

Iranian Scientists Use MOFs to Eliminate Dye Pollutants January 29th, 2015

Jobs

Secretary Vilsack Announces Partnership to Advance Commercial Potential of Cellulosic Nanomaterial from Wood December 11th, 2013

Cutting Away at the NRC's Research Capability December 6th, 2013

Project aims to mass-produce 'nanopetals' for sensors, batteries October 22nd, 2013

Governor Cuomo Announces 'Nano Utica' $1.5 Billion Public-Private Investment That Will Make the Mohawk Valley New York's Next Major Hub of Nanotech Research October 12th, 2013

Nanomedicine

Made-in-Singapore rapid test kit detects dengue antibodies from saliva: IBN's MedTech innovation simplifies diagnosis of infectious diseases January 29th, 2015

Iranian Researchers Planning to Produce Edible Insulin January 28th, 2015

Nanoparticles that deliver oligonucleotide drugs into cells described in Nucleic Acid Therapeutics January 28th, 2015

Nanoliposomes Help Efforts to Cure Bacterial Infections January 27th, 2015

Announcements

Advantest to Exhibit at SEMICON Korea in Seoul, South Korea February 4-6 Showcasing Broad Portfolio of Semiconductor Products, Technologies and Solutions January 29th, 2015

Park Systems Announces Innovations in Bio Cell Analysis with the Launch of Park NX-Bio, the only 3-in-1 Imaging Nanoscale Tool Available for Life Science Researchers January 29th, 2015

2015 Nanonics Image Contest January 29th, 2015

Iranian Scientists Use MOFs to Eliminate Dye Pollutants January 29th, 2015

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

2015 Nanonics Image Contest January 29th, 2015

OCSiAl supports NanoART Imagery Contest January 23rd, 2015

EnvisioNano: An image contest hosted by the National Nanotechnology Initiative (NNI) January 22nd, 2015

Laser-generated surface structures create extremely water-repellent metals: Super-hydrophobic properties could lead to applications in solar panels, sanitation and as rust-free metals January 20th, 2015

Nanobiotechnology

Spider electro-combs its sticky nano-filaments January 28th, 2015

Nanoshuttle wear and tear: It's the mileage, not the age January 26th, 2015

Engineering self-assembling amyloid fibers January 26th, 2015

DNA 'glue' could someday be used to build tissues, organs January 14th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE